Special Issue "Gene Therapy and Cancer: Current Developments"
Deadline for manuscript submissions: closed (30 June 2017).
Interests: epigenetics/genetics related to gene silencing; imprinting; cancer; progenitor cell formation; cancer progression and metastais; signaling regulating epigenetics events; combination therapy of cancers by HDAC inhibitors and other drugs; integrin signaling related to thrombosis; inhibition of apoptosis and motility in cancer cells; inhibition of syk tyrosine kinase and protease calpain related to platelet clot lysis
Special Issues and Collections in MDPI journals
Cancer is a complex disease precipitated by diverse mechanisms, as outlined in the Hallmarks of Cancer article. The abnormal states in numerous cancers include inherited genetic modifications and somatic mutations. Additionally, epigenetic modifications of chromatin and DNA methylation significantly regulate initiation and progression of carcinogenesis. Epigenetic alterations are reversible, but the majority of genetic alterations are irreversible. The current accepted treatment confronts these transformed cancer cells or tumors; however, does not perturb the genetic component.
In order to produce a definitive effect, therapies targeting genetic components need to be pursued. The gene therapy field is composed of wide-ranging therapeutic approaches used to correct aberrations produced by genetic alterations, which is often by insertion of normal genes into the cancerous genome to rectify the mistakes produced by the abnormal genes. In addition, rational incorporation of modified chromatin structures changes epigenetic regulations towards favorable outcomes. The last two decades have shown continuous development towards these goals, which are progressively being translated into clinical use. This Special Issue, “Gene Therapy and Cancer: Current Developments”, is designed to include articles that highlight new developments of gene therapy to treat cancer.
Dr. Sibaji Sarkar
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Gene Therapy
- Drug Resistant Cancer
- Cancer Stem Cells